COCRYSTAL PHARMA INC.

Cocrystal Pharma's Antiviral CDI-988 Shows Potent Activity Against Emerging Norovirus Variants

a month ago

• Cocrystal Pharma's oral antiviral candidate CDI-988 demonstrates potent activity against emerging GII.17 norovirus variants, which have recently overtaken GII.4 as the most prevalent strain in the US and Europe. • The pan-viral protease inhibitor targets a highly conserved region in viral proteases, showing broad-spectrum activity against both norovirus and coronavirus strains with a novel mechanism of action. • Following successful Phase 1 safety and tolerability results, Cocrystal plans to initiate a human challenge study in 2025 to evaluate CDI-988 as the first potential treatment and prevention option for norovirus infection.

Cocrystal Pharma Extends Phase 2a Trial of CC-42344 Influenza Inhibitor Due to Low Infection Rates

5 months ago

• Cocrystal Pharma is extending its Phase 2a trial for CC-42344 due to unexpectedly low influenza infection rates among participants. • The Phase 2a study aims to evaluate the safety, tolerability, antiviral activity, and pharmacokinetics of CC-42344, an oral PB2 inhibitor. • CC-42344 has demonstrated a favorable safety and tolerability profile, with no serious adverse events or drug-related discontinuations reported. • The company is working to amend the study protocol to ensure adequate infection rates for accurate antiviral data analysis.

Cocrystal Pharma and Chemomab Therapeutics Report Progress in Antiviral and Fibro-inflammatory Drug Development

6 months ago

• Cocrystal Pharma anticipates topline results from its Phase 2a influenza A challenge study with oral PB2 inhibitor CC-42344 by year-end. • Cocrystal Pharma's Phase 1 pan-norovirus/pan-coronavirus study with oral protease inhibitor CDI-988 is progressing, with topline results expected in late 2024 or early 2025. • Chemomab Therapeutics plans to meet with the FDA to discuss the design of a CM-101 registrational trial for primary sclerosing cholangitis (PSC). • Chemomab's CM-101 Phase 2 SPRING trial data will be presented at the AASLD conference, with preparations underway for a Phase 3 trial in late 2025.